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Abstract
Dendritic cells (DC) are able to elicit anti-tumoral CD8
+ T cell responses by cross-presenting exogenous antigens in
association with major histocompatibility complex (MHC) class I molecules. Therefore they are crucial actors in cell-based
cancer immunotherapy. Although apoptotic cells are usually considered to be the best source of antigens, live cells are also
able to provide antigens for cross-presentation by DC. We have recently shown that prophylactic immunotherapy by DC
after capture of antigens from live B16 melanoma cells induced strong CD8
+ T-cell responses and protection against a lethal
tumor challenge in vivo in C57Bl/6 mice. Here, we showed that DC cross-presenting antigens from live B16 cells can also
inhibit melanoma lung dissemination in a therapeutic protocol in mice. DC were first incubated with live tumor cells for
antigen uptake and processing, then purified and irradiated for safety prior to injection. This treatment induced stronger
tumor-specific CD8
+ T-cell responses than treatment by DC cross-presenting antigens from apoptotic cells. Apoptotic B16
cells induced more IL-10 secretion by DC than live B16 cells. They underwent strong native antigen degradation and led to
the expression of fewer MHC class I/epitope complexes on the surface of DC than live cells. Therefore, the possibility to use
live cells as sources of tumor antigens must be taken into account to improve the efficiency of cancer immunotherapy.
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Introduction
Dendritic cells (DC) are professional antigen-presenting cells
that are the most powerful stimulators of naive T cells, playing a
key role in the initiation of immune responses. They have
developed unique cross-presentation pathways allowing major
histocompatibility complex (MHC) class I–restricted presentation
of antigens of exogenous origin, taken up by endocytosis or
phagocytosis. Cross-presentation is crucial for the stimulation of
CD8
+ T lymphocytes and therefore induction of immunity and
tolerance to antigens that are not directly synthesized in the cytosol
of DC, such as antigens from tumors [1,2,3,4,5,6].
Given their unique properties, DC have been used with tumor-
associated antigens for active cancer immunotherapy [7]. To date,
different sources of antigens have been used to load DC: tumor-specific
proteins or synthetic peptides [8,9,10], peptides eluted from tumor cell
surface HLA molecules [11], apoptotic tumor cells [12,13,14,15],
tumor cell lysates [16,17,18], tumor cell/DC fusions [19].
Loading MHC class I and MHC class II molecules on DC with
peptides derived from defined tumor antigens is the most
commonly used strategy for DC vaccination, but this approach
presents several disadvantages: the restriction to a limited number
of HLA molecules, the limited number of well-defined tumor
antigens, the relatively rapid turnover of exogenous peptide-MHC
complexes and the induction of a restricted repertoire of T-cell
clones. An alternative is to load derivatives from whole tumor cells,
as this theoretically allows presentation of all possible epitopes,
even if undefined, by all HLA types. The parallel presentation of
both class I and II MHC-restricted antigens can promote a
stronger overall anti-tumor response and long-term cytotoxic
CD8
+ T-cell memory via CD4
+ T-cell help [20]. In addition,
the requirement for processing results in prolonged antigen
presentation [21].
Studies have focused on the use of dead (either apoptotic or
necrotic) tumor cells as a source of tumor antigens. In murine
models, immunization with DC that had phagocytosed apoptotic/
necrotic tumor cells induced good protection against tumors
[22,23]. In patients with different types of cancers, DC loaded with
autologous or allogeneic tumor-cells have also been used for
immunotherapy [12,13,14,15]. However, despite the elicitation of
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raised by preclinical studies. The tumor environment is strongly
immunosuppressive by different mechanisms, and only some types
of death induce immunogenic stress signals [24,25,26].
Besides dead cells, live cells can also be a source of antigen for
cross-presentation by DC [27,28,29], after antigen uptake through
nibbling, a mechanism related to trogocytosis [30]. Recently, we
have demonstrated that DC that had acquired antigens from live
B16 melanoma cells protected mice from lethal tumor challenge in
a prophylactic setting [29]. Here, we assessed the potential of DC
loaded with antigens from live tumor cells to control established
tumors, and we investigated activation and antigen availability
using live tumor cells compared to dead tumor cells.
Materials and Methods
Ethics statement
All experiments were performed according to the European
Community Council Directive of 11/24th/1986 (86/609/EEC)
and with permission of the French Veterinary Services (permit
number 75-1321) and approval of the Cochin General Animal
Facility Service (accreditation number A-75-14-02). All efforts
were made to minimize suffering.
Mice
Eight to twelve week-old C57Bl/6 mice obtained from Harlan
Laboratories were bred in the Cochin Institute specific pathogen-
free animal facility.
Cell culture and purification
B3Z cells and B16 F10 (B16) cells were maintained in complete
medium (RPMI 1640 Glutamax supplemented with 10% fetal calf
serum, 100 U/ml penicillin, 100 mg/ml streptomycin, 0.1 mM
non essential amino acids solution, 10 mM HEPES buffer solution
and 1 mM sodium pyruvate, all from Invitrogen). L cells
transfected with a form of ovalbumin (OVA) only expressed in
the cytoplasm, i.e. OVA-EGFP-DAP (L-OVA cells) were a kind
gift from K. Rock (University of Massachusetts Medical School,
Boston, MA)[31]. They were cultured in complete medium and
500 mg/ml G418 (Sigma-Aldrich). B3Z cells, lacZ-inducible CD8
+
T cell hybridoma which express b-galactosidase upon specific
recognition of the OVA257-264 (SIINFEKL)-H-2K
b complex [32],
were a kind gift from C. Leclerc (Institut Pasteur, France).
To avoid caspase-mediated cell death, cells were cultured in the
presence of 10 mM z-VAD FMK (Sigma-Aldrich). Alternatively,
apoptosis was induced by c-irradiation (100 Gy), then cells were
used after 48-hour incubation in complete medium. The
proportion of annexin V
+PI
- apoptotic cells was $70%.
For bone marrow-derived DC (BMDC) generation, bone
marrow cells from C57Bl/6 mice were depleted of red blood cells
using 0.84% ammonium chloride. Cells (2610
5/ml) were
resuspended in complete medium with 30 ml/ml of hybridoma
supernatant containing granulocyte-macrophage colony-stimulat-
ing factor (kind gift from David Gray, Royal Postgraduate
Hospital, London). Medium was replaced after 2 and 4 days.
Immature DC were obtained after 6 days.
For in vitro cross-presentation assays, BMDC were cultured for
16 h with different amounts of live or apoptotic cells in the
presence of lipopolysaccharide (LPS from E.Coli 0111:B4; 500 ng/
ml; Sigma-Aldrich) and DC were purified using CD11c microbe-
ads for positive immunomagnetic selection (Miltenyi Biotec).
Purified DC were cultured for 18 h with the B3Z-T cell
hybridoma. After addition of the CPRG substrate, optical density
was measured at 560 nm by an ELISA reader (Berthold CB911).
DC maturation was assessed after incubation with live or
apoptotic B16 cells with or without LPS and IFNc (20 ng/ml,
Roche). Twenty-four hours later, supernatants were collected to
assess cytokine production by ELISA and DC were used for flow
cytometry.
Anti-tumor protection in vivo
On day 0, mice were injected i.v. with 10
6 B16 cells to induce
lung tumors. DC were cultured for 16 hours in the presence of
LPS (500 ng/ml) and IFNc (20 ng/ml), either alone or with B16
derived MHC class I-restricted synthetic peptides (gp10025–33 and
TRP2181–188,1 0mM each), or with live B16 cells in the presence
of z-VAD, or with apoptotic B16 cells. DC (5610
5) were then
washed, purified, c-irradiated (100 Gy) to eliminate any residual
live tumor cells, and immediately injected i.v into C57Bl/6 mice
on days 3 and 10. On day 15, tumor nodules were counted on the
lung surface. Splenocytes were restimulated for 36 hours with c-
irradiated B16 cells or 1 mM peptide (gp10025–33 or TRP2181–188).
The ability of stimulated splenocytes to produce IFNc was assayed
by ELISPOT or flow cytometry.
Flow cytometric analysis
DC maturation was evaluated by immunofluorescence labeling
with the following mAb: anti-CD11c-PE-Cy7, anti-CD80-FITC,
anti-CD86-APC, anti-IA
b-PE. T cells were labeled with the
following mAb: anti-CD3-PE-Cy7, anti-CD4-biotin, anti-CD8a-
APC-H7 and anti-IFNc-APC. The anti-CD11c-PE-Cy7 mAb
was from eBiosciences, the others from BD. Labeling was
performed at 4uC using PBS containing 5% fetal calf serum
and 5 mM EDTA (Sigma). Cells were incubated with purified
anti-CD16/32 (2.4G2) mAb to block Fc receptors (BD) for
20 min. Then they were labeled with conjugated antibodies for
further 20 min. For biotinylated antibodies, streptavidin-PerCP
(BD Biosciences) was added in a second step for 15 min. For
intracellular IFNc labeling, spleen cells were restimulated for
4 hours at 37uC in 5% CO2 at 10
6 cells/ml in complete medium
with 0.5 mg/ml phorbol myristate acetate (PMA) and 0.5 mg/ml
ionomycin in the presence of Golgi Plug (BD), and labeled with
anti-CD3, anti-CD4, anti-CD8 mAb, then intracellularly with an
anti-IFNc mAb (Intracellular staining kit, BD). Annexin-V
staining was performed using the Annexin-V apoptosis detection
kit from BD Bioscience. Events were acquired using a FACS
CANTO or a BD LSR II flow cytometer and analyzed using
Diva (Version 6.1.1, BD Biosciences) followed by FlowJo (Version
7.2.5; TreeStar).
ELISPOT assays
PVDF microplates (Millipore) were coated overnight at 4uC
with 4 mg/ml of an anti-mouse IFNc rat monoclonal antibody
(AN18, Mabtech AB) diluted in PBS. After extensive washes, wells
were blocked with RPMI containing 10% AB human serum
(ABCYS) for 2 hours at 37uC. Three 610
5 splenocytes were
incubated overnight with one of the peptides corresponding to a
specific epitope (final concentration 10 mg/ml) or with B16
melanoma cells. The plates were then washed, incubated with
1 mg/ml biotinylated anti-mouse IFNc rat monoclonal antibody
(R4-6A2, Mabtech AB) diluted in PBS for 2 hours at 37uC, and
then overnight at 4uC. Plates were subsequently incubated with
extravidine-coupled alkaline phosphatase (Sigma-Aldrich) diluted
in PBS. After adding the BCIP/NBT substrate (Sigma-Aldrich),
IFNc spot forming cells were counted using a BioReader 5000F
ELISPOT reader and expressed as the number of spots per million
cells tested.
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Culture supernatants were assayed for IL-12p70 and IL-10
using kits from Ebioscience according to supplier instructions.
Optical density was measured at 560 nm using an ELISA Berthold
CB911 reader.
Western Blots
Live or apoptotic B16 and L cells were scraped at 4uCi n
CHAPS buffer (1% 3-[(3-Cholamidopropyl)dimethylammonio]-
1propanesulfonate, 10 mM Hepes pH 7.4, 150 mM NaCl, 10%
glycerol; Sigma-Aldrich) containing proteases inhibitors (Com-
plete EDTA-free tablets, Roche) and 0.2 mM sodium orthova-
nadate (Sigma-Aldrich). Protein concentration was measured by
spectrometry at 280 nm (NanoDrop, Labtech). Cell lysates were
boiled at 95uC for 5 min in sample application buffer containing
2-mercaptoethanol (Lane Marker Reducing Sample buffer;
Thermosciences). Fifty mg of proteins (for B16 cells), or 25 mg
of proteins (for L cells), from each sample were separated by
SDS/10%PAGE (ready-to-use; BioRad) for 1 hour at 150 V
and transferred onto a nitrocellulose membrane for 1 hour at
80 V. Membranes were then blocked for 2 hours with TBS/
0,05% Tween buffer plus 5% milk (BioRad). Membranes were
probed with a polyclonal rabbit antibody to OVA (for OVA-
EGFP-DAP cells), a polyclonal goat antibody to gp100, a
polyclonal goat antibody to TRP2 (for B16 cells) or a polyclonal
goat antibody to actin overnight at 4uC and incubated with
horseradish peroxidase-conjugated antibodies to rabbit IgG or to
goat IgG (all antibodies from Santa Cruz Biotechnology) for
1 hour. Visualization was carried out with enhanced chemilu-
minescence (GE Healthcare). Bands were analyzed using a LAS
300S reader.
Figure 1. DC cultured with live B16 cells induced strong protection against tumor in a therapeutic setting. A, time schedule outlining
the different stages as used in the experiments. Five C57BL/6 mice per group were inoculated i.v. with 1.10
6 B16 cells at day 0. At days 3 and 10, mice
were immunized with 0,5.10
6 of purified and irradiated DC that were previously cultured for 16 h in the presence of LPS and IFNc, with either culture
medium (DC), or gp10025–33 and TRP2181–188 peptides (DC-peptides), or live (zVAD treated) B16 cells (DC-B16 zVAD) or apoptotic (c-irradiated) B16
cells (DC-B16c). B, B16 cell apoptosis was evaluated by annexin-V staining (solid lines) compared to no staining (dotted lines) and the mean number
6 SEM of the Annexin-positive events is shown. At day 15, mice were sacrificed, lung tumors were counted (C) and T cell responses were evaluated in
the spleen. D, Splenocytes were restimulated with gp10025–33 or TRP2181–188 peptides or B16 cells or culture medium and tested in an IFNc ELISPOT
assay. E, After B16 restimulation, splenocytes were also stimulated with PMA and ionomycin and then labeled with anti-CD3, anti-CD8 and
intracellularly with anti-IFNc antibodies. Events were gated on CD3
+CD8
+ splenocytes and IFNc production was mesured by flow cytometry. The
mean 6 SEM of data from 5 mice per group are shown for an experiment representative of two independent experiments. The significance of
differences between series was assessed by unpaired t test.
doi:10.1371/journal.pone.0019104.g001
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PLoS ONE | www.plosone.org 3 April 2011 | Volume 6 | Issue 4 | e19104Figure 2. DC maturation after culture with live or apoptotic B16 cells. DC were cultured with live (zVAD treated) or apoptotic (c-irradiated)
B16 cells for 24 h in the presence of culture medium or LPS and IFNc. The expression of maturation molecules was then tested by flow cytometry.
One representative experiment out of three independent experiments is shown.
doi:10.1371/journal.pone.0019104.g002
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The significance of differences between series of results was
assessed by unpaired t test (Prism 5, GraphPad Software). P
values,0.05 were considered significant.
Results
DC loaded with live melanoma cells induced protection
against B16 tumors in a therapeutic setting and a
stronger CD8
+ T cell response than DC cultured with
apoptotic melanoma cells
After reporting that DC cultured with live B16 melanoma cells
induced a strong protection against a lethal tumor challenge in a
preventive immunization model [29], we tested this immunization
in a therapeutic setting (Fig. 1A). At day 0, C57BL/6 mice were
inoculated i.v. with B16 cells. Bone marrow-derived DC were
cultured for 16 h in the presence of LPS and IFNc, with either live
B16 cells and the caspase inhibitor zVAD to avoid caspase-
mediated apoptosis (DC-B16 zVAD), or apoptotic B16 cells (DC-
B16c) (Fig. 1B), or tumor specific MHC class I-restricted peptides
(gp10025–33 and TRP2181–188, DC-peptides), or medium alone
(DC). DC were purified to 98% by positive selection, irradiated at
100 Gy to avoid injecting any residual live tumor cell, then
injected i.v. 3 and 10 days after tumor inoculation. At day 15, mice
treated with DC alone had 406650 tumors in their lungs, whereas
mice treated with DC cultured with live B16 cells were strongly
protected as they only displayed 28614 tumors. Surprisingly,
protection was more efficient using DC cultured with live rather
than with apoptotic tumor cells (Fig. 1C, p=0.0029). IFNc
responses to gp10025–33 or TRP2181–188 or to B16 tumor cells were
reproducibly higher with DC-B16 zVAD than with DC-B16c
(Fig. 1D). As expected, immunization with DC cultured with B16
cells induced higher responses to the tumor itself than immuni-
zation with DC-peptides. Immunization with peptide-loaded DC
yielded similar numbers of IFNc positive spots in response to
either B16 cells or to peptide-loaded DC, whereas immunization
with live or apoptotic cell-loaded DC yielded much higher
responses to B16 cells than to peptide-loaded DC, indicating
stimulation of a larger set of clones responding to a broader
antigenic repertoire, including responses to TRP2181–188 and
gp10025–33 (Fig. 1D). Indeed, B16 cells provide many more tumor
epitopes, including undefined epitopes, than the two peptides.
IFNc responses to B16 cells were induced in CD8
+CD3
+ T cells in
the spleens from mice immunized with DC-B16 specifically
compared to spleens from mice immunized with DC or DC-
peptides (Fig. 1E), showing MHC-class I-restricted responses




+ T cells (not shown). Therefore, DC cultured
with live tumor cells, purified and strongly irradiated to prevent
Figure 3. DC cytokine profile after culture with live or apoptotic B16 cells. DC were cultured alone (DC) or with live (zVAD treated) or
apoptotic (c-irradiated) B16 cells for 24 h and stimulated or not with LPS and IFNc. As controls, B16 zVAD and B16c cells were also cultured alone. DC
were then assessed for their ability to produce IL-12p70 (A) or IL-10 (B) by ELISA. In the upper panels, data from one out of three independent
experiments are shown. In the bottom panels, for LPS and IFNc stimulation, relative IL-12p70 and IL-10 productions are expressed as a percentage of
the cytokine production obtained for DC alone. Mean percentage values6SEM are shown. The significance of differences between series of results
was assessed using a paired t test (n=3, 3 independent experiments).
doi:10.1371/journal.pone.0019104.g003
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protection and a stronger immunity in a therapeutic protocol than
DC cultured with apoptotic tumor cells.
Culture of DC with apoptotic B16 cells led to higher IL-10
production than culture with live B16 cells
We next documented the impact of culture with either live or
apoptotic B16 cells on DC maturation. DC were cultured with live
(zVAD treated) or apoptotic (c-irradiated) B16 cells for 24 h while
maturation was induced or not using LPS and IFNc. First, DC
maturation was assessed by labeling for MHC class II molecules
and the costimulatory CD80 or CD86 molecules. Without
stimulation, DC cultured either with live cells or apoptotic cells
displayed a phenotype consistent with a slight maturation. On the
contrary after stimulation with LPS and IFNc, DC cultured with
apoptotic or live B16 cells were less mature than DC cultured
alone. The maturation phenotype of DC was slighly higher after
culture with apoptotic than with live B16 cells (Fig. 2). In the same
cultures, we also examined the production of the proinflammatory
cytokine IL-12 (p70) and the anti-inflammatory cytokine IL-10. As
expected, live or irradiated B16 cells did not produce any IL-
12p70 or IL-10 even after stimulation with LPS and IFNc.D C
cultured with live or apoptotic cells produced similar concentra-
tions of IL-12p70 after stimulation with LPS and IFNc (Fig. 3A).
On the contrary, DC cultured with apoptotic B16 cells produced
more IL-10 than DC cultured with live B16 cells or cultured alone
(Fig. 3B). Therefore, culture of DC with apoptotic B16 cells
compared to live B16 cells led to slightly more phenotypic
maturation, and significantly more IL-10 secretion, which might
decrease CD8
+ T lymphocyte stimulation.
Live cells improved cross-presentation by DC by keeping
antigens in a more native form than apoptotic cells
One parameter that controls cross-presentation efficiency is the
amount of antigen accessible to the DC [33]. We performed
western blots to evaluate the quality and the amount of two tumor
antigens, gp100 and TRP2, in live or apoptotic B16 cells. We
observed that both antigens were strongly degraded in apoptotic
melanoma cells, while they were conserved in a native form in live
cells (Fig. 4A). To examine the impact of the conservation of native
antigen on cross-presentation, we used L cells expressing cytosolic,
non-secreted ovalbumin (L-OVA) as a source of antigen, so as to
evaluate the expression level of MHC class I-CD8
+ T cell OVA
epitope (SIINFEKL) complexes on DC with the B3Z hybridoma.
We could not use OVA-expressing B16 cells since they expressed a
secreted form of OVA. We first confirmed that, similarly to gp100
and TRP2 in B16 cells, OVA antigen was strongly degraded in
apoptotic L-OVA cells, while it was conserved in a native form in
live cells (Fig. 4B). After culture of DC with live or apoptotic
L-OVA cells at different ratios, cross-presentation was then
Figure 4. More native antigen in live than in apoptotic donor cells: improved antigen crosspresentation by DC. A, B, 30.10
6 live (zVAD
treated) or apoptotic (c-irradiated) B16 cells (A) or L-OVA cells (B) were lysed for protein extraction. Lysates from B16 cells were analysed using anti-
gp100, anti-TRP2 and anti-actin antibodies (A). Lysates from L-OVA cells were analysed using anti-OVA and anti-actin antibodies antibodies (B). Anti-
actin antibodies were used as controls. C, DC were cultured with different numbers of live (filled triangle) or apoptotic (open triangle) L-OVA cells or
live L cells (filled square). DC were then purified by magnetic sorting using anti-CD11c microbeads and cultured with B3Z-T cells hybridoma cells for
18 h. Activation after recognition of the SIINFEKL-K
b complex was detected by optical density measurement at 560 nm after addition of the CPRG
substrate. The significance of differences between series of results was assessed using a two-tailed unpaired t test. **p,0.01, *p,0,05, n.s. not
significant. Mean 6 SEM, representative of two independent experiments.
doi:10.1371/journal.pone.0019104.g004
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apoptotic cells than live cells were necessary to reach the maximal
level of MHC class I-SIINFEKL complexes, which was lower
using apoptotic cells. Thus, B3Z activation was significantly higher
when DC were cultured with live than with apoptotic antigen
donor cells. Therefore, better native antigen conservation in live
cells compared to apoptotic cells seems to induce the expression of
a higher number of MHC class I-epitope complexes on DC.
Discussion
We have previously reported that cross-presentation of antigens
from live B16 melanoma cells by DC induced a strong protection
against a lethal tumor challenge in a preventive immunization
model [29]. Here, we showed that injection of DC loaded with live
B16 melanoma cells also protected mice from tumor dissemination
in a therapeutic model. In the prophylactic immunization model,
T cell responses were consistently stronger when DC were cultured
with live melanoma cells than with apoptotic cells [29]. Here in the
therapeutic model, DC cultured with live tumor cells induced
more efficient protection and a stronger immunity than DC
cultured with apoptotic tumor cells. We investigated what might
confer a stronger immunogenicity to live cells.
The ability of DC to trigger an effective T cell response is
dependent on their state of maturation and on cytokine
production. We observed slightly higher MHC and costimulatory
molecule expression levels after culture of DC with apoptotic
compared to live cells, but similar IL-12 production levels. IL-12 is
required for the polarization of Th1 responses, which in turn
promote the activation of CD8
+ T cells into effector cytotoxic T
lymphocytes, allowing the clearance of infected or transformed
cells. On the contrary, IL-10, mainly secreted by DC and
regulatory T cells, is rather a tolerogenic cytokine, which can
inhibit T cell activation. [34]. DC cultured with apoptotic cells
produced more IL-10 than DC cultured with live cells, conferring
them potential tolerogenic properties, particularly when DC were
matured with LPS and IFNc, which corresponds to the
maturation stimulus used in our immunotherapeutic protocol.
The conservation state of antigens is a very important
parameter in DC-based immunotherapy since the induction of
an effective T cell response depends on the quality and quantity of
the antigen [33]. It has already been shown that antigens are
degraded in apoptotic bodies [35]. Moreover, it has also been
proposed that pre-processing of antigens in apoptotic or
autophagic cells could improve their cross-presentation by DC
[36,37]. Here, western blots showed that antigens were strongly
degraded in apoptotic cells, while they were conserved in a native
form in live cells. The degradation of antigens in apoptotic cells
could have an impact on cross-presentation, making it less
effective. Indeed, a dose-response experiment showed that the
number of MHC class I-SIINFEKL complexes on DC was greater
with live cells than with apoptotic cells as antigen-donor cells.
Thus, the impact of the conservation status of antigen on cross-
presentation may be considered in two ways. On the one hand,
death by apoptosis or autophagy could provide pre-processed
antigens, almost ‘‘ready-to-use’’ for DC [38,39]. On the other
hand, our data show that live cells can be a source of native
antigen, the correct processing of which would be under full
control of the specialized DC.
Until recently, only apoptotic cells were considered as an
effective cellular source of antigen for cross-presentation, and
immunization protocols using DC loaded with whole tumor cells
have been carried out with apoptotic tumor cells, neglecting the
possibility to use live tumor cells. In a preliminary prophylactic
immunization experiment where we injected purified, but
unirradiated DC before tumor challenge, we suspected that
despite protection against the challenge, a larger tumor in an
immunized mouse than in controls might be related to a
contaminating tumor cell in the DC preparation. Consequently,
we chose to use strongly irradiated DC to prevent inoculation of
proliferating tumor cells, and ensure safety. Irradiation of the DC
did not preclude antitumor protection nor T cell responses.
Therefore, live tumor cells should be taken into account as a
source of antigens to load DC and improve the efficiency of tumor
immunotherapy protocols, because they supply native tumor
antigens that can be efficiently processed by specialized DC for
cross-presentation.
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